Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597437 | 0.86 | OPRM1 (0.39) | BACE1BACE2APPCTSDOPRM1 | |
| SCHEMBL4599722 | 0.84 | APP (0.38) | BACE1BACE2APPCTSDOPRM1 | |
| SCHEMBL5521889 | 0.84 | BACE1 (0.40) | BACE1BACE2APPCTSDOPRM1 | |
| SCHEMBL5515650 | 0.83 | BACE1 (0.48) | BACE1BACE2APPCTSD | |
| SCHEMBL4597602 | 0.82 | BACE1 (0.46) | BACE1BACE2APPCTSD | |
| SCHEMBL4599019 | 0.80 | POLB (0.37) | BACE1BACE2APPCTSDOPRM1 | |
| SCHEMBL5517793 | 0.79 | BACE1 (0.43) | BACE1BACE2APPCTSD | |
| SCHEMBL5526888 | 0.79 | BACE1 (0.42) | BACE1BACE2APPCTSD | |
| SCHEMBL5521710 | 0.78 | CHRM2 (0.40) | BACE1BACE2APPCTSDOPRM1 | |
| SCHEMBL4599371 | 0.76 | APP (0.40) | BACE1BACE2APPCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910309-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.